康柏西普在眼部新生血管性疾病中的应用进展  

Progress of the application of Conbercept in ocular neovascular diseases

作　　者：陈晓冬 陆慧琴[1] 王彤[1] Xiao-Dong Chen;Hui-Qin Lu;Tong Wang(Xi’an No.1 Hospital,Shaanxi Institute of Ophthalmology,the First Affiliated Hospital of Northwestern University,Xi’an 710002,Shaanxi Province,China)

机构地区：[1]中国陕西省西安市第一医院陕西省眼科研究所西北大学附属第一医院,710002

出　　处：《国际眼科杂志》2022年第8期1361-1364,共4页International Eye Science

基　　金：白求恩·朗沐中青年眼科科研基金(No.BJ-LM202009);陕西省重点研发计划项目(No.2020SF-272,2022SF-312);西安市卫生科研人才培训项目(No.J201902040)。

摘　　要：康柏西普是中国自主研发的一种抗血管内皮生长因子新药。自从2013年被中国国家食品药品管理总局批准用于临床,康柏西普在治疗湿性年龄相关性黄斑变性、脉络膜新生血管、黄斑水肿等眼部新生血管性疾病过程中显示出可靠的安全性和疗效。针对不同的疾病,康柏西普的治疗策略有所不同。本文就近年来康柏西普在湿性年龄相关性黄斑变性、糖尿病性黄斑水肿、病理性近视脉络新生血管、新生血管性青光眼、未成熟儿视网膜病变、角膜新生血管等眼部新生血管性疾病中的应用进展进行综述,总结探讨康柏西普的用药适应证、给药方案和治疗效果。期待康柏西普的用药适应证会更广,给药方案会更多,为眼部新生血管性疾病的治疗带来新的思路。Conbercept is a novel anti-vascular endothelial growth factor drug independently developed by China. Since it was approved for clinical application by the State Food and Drug Administration of China in 2013, conbercept has shown reliable safety and efficacy in the treatment of ocular neovascular diseases such as wet age-related macular degeneration, choroidal neovascularization and macular edema. For different diseases, the treatment strategies of conbercept are different. This article mainly reviews the application progress of conbercept in ocular neovascularization related diseases including wet age-related macular degeneration, diabetic macular edema, pathologic myopia choroidal neovascularization, neovascular glaucoma, retinopathy of prematurity and corneal neovascularization, and summarizes and explores the indications, administration scheme and therapeutic effect of conbercept. It is expected that the indications of conbercept will be wider and the administration scheme will be more given, and the usage of conbercept will bring new ideas for the treatment of ocular neovascular diseases.

关 键 词：康柏西普 血管内皮生长因子 湿性年龄相关性黄斑变性 脉络膜新生血管 黄斑水肿 新生血管性青光眼 未成熟儿视网膜病变 角膜新生血管 

分 类 号：R77[医药卫生—眼科]